Handelsavisen
prelaunch
Companies Healthcare MDLN.JK
MD
MDLN.JK IDX (Jakarta) Diversified Medical Equipment & Supplies

Modernland Realty Tbk PT

$51,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-128,0 %
ROE
-9,7 %
Net margin
-168,3 %
Debt / equity
1,94
Beta
52w range
Volume
17
Day range
Prev close
$35,84
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Modernland Realty Tbk PT is a real estate company engaged in real estate rental, development, and operations, generating revenue primarily through property development and leasing activities.

Business. Modernland Realty Tbk PT (MDLN.JK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY28 analysts
22 buy6 hold0 sell
Avg 12m price target53,56

Analyst recommendations

28 analysts · consensus Buy
Buy22
Hold6
Sell0
12-month price target
53,56
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
28 analysts · indicative
Ownership
not yet wired
Profitability
-9,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MDLN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MDLN.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Modernland Realty Tbk PT (MDLN.JK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Modernland Realty Tbk PT has a liquidity risk profile that is currently rated as medium, with a debt-to-equity ratio of 1.94 and a current ratio of 0.84, indicating that the company's short-term liabilities exceed its short-term assets. The company's cash and equivalents amount to only 578,224,660 IDR, which is significantly lower than its long-term debt of 6,836,641,640,720 IDR, further highlighting the liquidity constraints.

    The company's profitability is under significant pressure, with a return on equity of -9.67% and a return on assets of -2.5%, both of which are well below the typical performance metrics for the real estate industry. The operating income is negative at -25,962,265,574 IDR, and the net income is also negative at -341,452,998,760 IDR, indicating a substantial decline in operational performance.

    Modernland Realty Tbk PT's revenue is primarily concentrated in its core real estate operations, with no disclosed geographic diversification or segment breakdown provided in the available data. The lack of segmental or geographic data limits the ability to assess the company's exposure to different markets or product lines.

    The company's growth trajectory is currently negative, with a net income decline and a free cash flow of -330,444,193,390 IDR, indicating a lack of cash generation from operations. The capital expenditure of -11,496,443,940 IDR suggests that the company is not investing in new projects or infrastructure, which could further hinder its ability to generate future revenue.

    The risk assessment for Modernland Realty Tbk PT includes a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting its financial obligations. The dilution risk is currently low, with no significant dilution sources identified in the available data.

    Recent events and filings indicate that the company is facing financial challenges, with a last actual EPS of -142.63 IDR, reflecting the company's current earnings performance. The lack of positive earnings and the negative cash flow suggest that the company may need to seek additional financing or implement cost-cutting measures to stabilize its financial position.

    Key takeaways
    • Modernland Realty Tbk PT is experiencing significant financial distress, with negative operating and net income.
    • The company's liquidity position is weak, with a current ratio of 0.84 and a debt-to-equity ratio of 1.94.
    • The company's profitability metrics, including return on equity and return on assets, are negative and below industry norms.
    • The company is not generating positive free cash flow and is not investing in new projects.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk.
    • The company's recent earnings performance is negative, with a last actual EPS of -142.63 IDR.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Analysts project 5% upside to a mean price target of 53.56, reflecting a consensus buy recommendation from 28 analysts.

    Free cash flow surged 300.8% year-over-year to 279.5 billion IDR, indicating significant improvement in cash generation capabilities.

    Operating income expanded 237.4% year-over-year to 665.3 billion IDR, demonstrating strong operational leverage and profitability recovery.

    The company maintains a healthy current ratio of 4.29, suggesting strong short-term liquidity to meet immediate financial obligations.

    Net income improved by 337% year-over-year to 241.7 billion IDR, marking a substantial turnaround from previous losses.

    BEAR CASE · 3

    The company faces high credit risk, signaling potential difficulties in meeting debt obligations or servicing existing liabilities.

    Net margin of -1.68% ranks in the bottom quartile of the sector, highlighting persistent profitability challenges relative to peers.

    Debt-to-equity ratio of 1.94 is in the bottom quartile of the cohort, indicating higher financial leverage and risk than peers.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2019-10-31
    Q3 2019 · Quarter highlights

    Revenue IDR 305.32B; Operating income -IDR 430.37B.

    RevenueIDR 305.32B
    Operating income-IDR 430.37B
    Net income-IDR 524.73B
    Free cash flow-IDR 510.16B
    EPS
    Operating cash flow-IDR 5.00B
    Financials
    Income statement
    RevenueIDR 305.32B
    Gross profitIDR 153.53B
    Operating income-IDR 430.37B
    Net income-IDR 524.73B
    Margins
    Gross margin50.3%
    Operating margin-141.0%
    Net margin-171.9%
    FCF margin-167.1%
    Balance sheet
    Total assetsIDR 13.56T
    Total liabilitiesIDR 10.11T
    Total equityIDR 3.45T
    Cash & equivalentsIDR 578.2M
    Long-term debtIDR 6.82T
    Cash flow
    Operating cash flow-IDR 5.00B
    CapEx-IDR 20.09B
    Free cash flow-IDR 510.16B
    SBC
    P&L flow · revenue → net income
    Revenue IDR 305.32BOperating costs IDR 735.69BTax IDR 94.36BNet income IDR 524.73B
    Highlights
    • Revenue IDR 305.32B
    • Operating income -IDR 430.37B
    • Net margin -171.9%

    Valuation FY

    Market price
    $51,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $3.53T
    Net cash
    -$6.84T
    Current ratio
    0.8
    Debt / equity
    1.9
    ROA
    -2.5%
    ROE
    -9.7%
    Cash conversion
    5.0%
    CapEx / revenue
    -5.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Life Science Instruments & Consumables
    low · business_description · 2026-07-03
    Protective Apparel & Gloves
    low · business_description · 2026-07-03
    Surgical Instruments & Equipment
    low · business_description · 2026-07-03
    Urology & Incontinence Care
    low · business_description · 2026-07-03
    Wound Care Products
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)MDLN 11,0% · rank #3 of 84

    Business relationships

    Business relationships128 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries128
    EX21:0167f705028eEX21:0167f705028eSubsidiarie97%
    EX21:024120e8cd70EX21:024120e8cd70Subsidiarie97%
    EX21:0806c5671c63EX21:0806c5671c63Subsidiarie97%
    EX21:08f26cf10c2cEX21:08f26cf10c2cSubsidiarie97%
    EX21:098b12509834EX21:098b12509834Subsidiarie97%
    EX21:0a15db5686b4EX21:0a15db5686b4Subsidiarie97%
    EX21:0a5f39f62700EX21:0a5f39f62700Subsidiarie97%
    EX21:0ab0ad97c06eEX21:0ab0ad97c06eSubsidiarie97%
    EX21:0b4e733b33b4EX21:0b4e733b33b4Subsidiarie97%
    EX21:0db0ca95b335EX21:0db0ca95b335Subsidiarie97%
    EX21:0e044e5c3bceEX21:0e044e5c3bceSubsidiarie97%
    EX21:0fda18eafb15EX21:0fda18eafb15Subsidiarie97%
    EX21:127fa9ef4df8EX21:127fa9ef4df8Subsidiarie97%
    EX21:1459d0334f54EX21:1459d0334f54Subsidiarie97%
    EX21:17123d52ec38EX21:17123d52ec38Subsidiarie97%
    EX21:1a2d24f63dc9EX21:1a2d24f63dc9Subsidiarie97%Source ↗
    EX21:1b205e5bc1abEX21:1b205e5bc1abSubsidiarie97%
    EX21:1b34b174b26aEX21:1b34b174b26aSubsidiarie97%
    EX21:1b4d24230efeEX21:1b4d24230efeSubsidiarie97%
    EX21:1c6abeaf5807EX21:1c6abeaf5807Subsidiarie97%
    EX21:1c9fcf1f738dEX21:1c9fcf1f738dSubsidiarie97%
    EX21:1ec0dfa0e496EX21:1ec0dfa0e496Subsidiarie97%
    EX21:1ed6c517e54aEX21:1ed6c517e54aSubsidiarie97%
    EX21:233eb0f3f2d1EX21:233eb0f3f2d1Subsidiarie97%
    EX21:27c0fbec0184EX21:27c0fbec0184Subsidiarie97%
    EX21:28272d57bed6EX21:28272d57bed6Subsidiarie97%
    EX21:2a02ed3f5b38EX21:2a02ed3f5b38Subsidiarie97%
    EX21:2b840121e3d7EX21:2b840121e3d7Subsidiarie97%
    EX21:2d2ffa68b40eEX21:2d2ffa68b40eSubsidiarie97%
    EX21:2de39c4c0cf8EX21:2de39c4c0cf8Subsidiarie97%
    EX21:2e617cbfc386EX21:2e617cbfc386Subsidiarie97%
    EX21:2e89b18b2d48EX21:2e89b18b2d48Subsidiarie97%
    EX21:2faf996ce4a3EX21:2faf996ce4a3Subsidiarie97%
    EX21:32be9743e5b6EX21:32be9743e5b6Subsidiarie97%
    EX21:3651e4e6850aEX21:3651e4e6850aSubsidiarie97%
    EX21:368c9edf1babEX21:368c9edf1babSubsidiarie97%
    EX21:3b19ff78814cEX21:3b19ff78814cSubsidiarie97%
    EX21:3f7b644fc808EX21:3f7b644fc808Subsidiarie97%
    EX21:433ed2ce6551EX21:433ed2ce6551Subsidiarie97%
    EX21:46b1c42e4f9dEX21:46b1c42e4f9dSubsidiarie97%
    EX21:47647b8f5022EX21:47647b8f5022Subsidiarie97%Source ↗
    EX21:48675f40db01EX21:48675f40db01Subsidiarie97%
    EX21:49259311691fEX21:49259311691fSubsidiarie97%
    EX21:4a5365dce369EX21:4a5365dce369Subsidiarie97%
    EX21:4a96d0271e38EX21:4a96d0271e38Subsidiarie97%
    EX21:4af7f262ce09EX21:4af7f262ce09Subsidiarie97%
    EX21:4ebb7d17a9d1EX21:4ebb7d17a9d1Subsidiarie97%
    EX21:4f4f0665c1b7EX21:4f4f0665c1b7Subsidiarie97%
    EX21:4fe9412dd54aEX21:4fe9412dd54aSubsidiarie97%
    EX21:502b92e48a6dEX21:502b92e48a6dSubsidiarie97%
    EX21:51553f5a2415EX21:51553f5a2415Subsidiarie97%
    EX21:548b08caf2aaEX21:548b08caf2aaSubsidiarie97%
    EX21:5641817166b1EX21:5641817166b1Subsidiarie97%
    EX21:59a0a6db5b7aEX21:59a0a6db5b7aSubsidiarie97%
    EX21:5aedc9c6f8ccEX21:5aedc9c6f8ccSubsidiarie97%
    EX21:5bc825eb1a58EX21:5bc825eb1a58Subsidiarie97%
    EX21:5bf77352a2cfEX21:5bf77352a2cfSubsidiarie97%
    EX21:5c12268a5361EX21:5c12268a5361Subsidiarie97%
    EX21:5e67a7b6ce89EX21:5e67a7b6ce89Subsidiarie97%
    EX21:5f60d31a04e3EX21:5f60d31a04e3Subsidiarie97%
    EX21:60dce2224c40EX21:60dce2224c40Subsidiarie97%
    EX21:618593b10ddfEX21:618593b10ddfSubsidiarie97%
    EX21:62f8e499260dEX21:62f8e499260dSubsidiarie97%
    EX21:643aae12af79EX21:643aae12af79Subsidiarie97%
    EX21:67cd5b640286EX21:67cd5b640286Subsidiarie97%
    EX21:67d2c5a3eed6EX21:67d2c5a3eed6Subsidiarie97%
    EX21:69dfc53781d3EX21:69dfc53781d3Subsidiarie97%
    EX21:6d3acd5e74faEX21:6d3acd5e74faSubsidiarie97%
    EX21:6d5df86a8f0dEX21:6d5df86a8f0dSubsidiarie97%
    EX21:6e09abad949cEX21:6e09abad949cSubsidiarie97%
    EX21:6f5c38dc34d1EX21:6f5c38dc34d1Subsidiarie97%
    EX21:70db93fffabeEX21:70db93fffabeSubsidiarie97%
    EX21:795fae40c31eEX21:795fae40c31eSubsidiarie97%
    EX21:7b496b8027f9EX21:7b496b8027f9Subsidiarie97%
    EX21:7c50e9370e99EX21:7c50e9370e99Subsidiarie97%
    EX21:8010f90d8ed0EX21:8010f90d8ed0Subsidiarie97%
    EX21:82e3f45d9240EX21:82e3f45d9240Subsidiarie97%
    EX21:83fcebbe4076EX21:83fcebbe4076Subsidiarie97%
    EX21:842d4a67be19EX21:842d4a67be19Subsidiarie97%
    EX21:843185181483EX21:843185181483Subsidiarie97%
    EX21:8522550fb8b7EX21:8522550fb8b7Subsidiarie97%
    EX21:87e5f96887eeEX21:87e5f96887eeSubsidiarie97%
    EX21:889504817f1eEX21:889504817f1eSubsidiarie97%
    EX21:89955dd85df1EX21:89955dd85df1Subsidiarie97%
    EX21:8b5de79d5227EX21:8b5de79d5227Subsidiarie97%
    EX21:8d0bcb997b15EX21:8d0bcb997b15Subsidiarie97%
    EX21:8e179ec60cbcEX21:8e179ec60cbcSubsidiarie97%
    EX21:8f10222217a5EX21:8f10222217a5Subsidiarie97%
    EX21:984e605466b3EX21:984e605466b3Subsidiarie97%
    EX21:99bda758cd7cEX21:99bda758cd7cSubsidiarie97%
    EX21:9ef634b64b9aEX21:9ef634b64b9aSubsidiarie97%
    EX21:a35ba5485a6aEX21:a35ba5485a6aSubsidiarie97%
    EX21:a8eca0e3d325EX21:a8eca0e3d325Subsidiarie97%
    EX21:b0e84014cab6EX21:b0e84014cab6Subsidiarie97%
    EX21:b3786438d50fEX21:b3786438d50fSubsidiarie97%
    EX21:b52994327fefEX21:b52994327fefSubsidiarie97%
    EX21:bd9fcdf026efEX21:bd9fcdf026efSubsidiarie97%
    EX21:c0b78a1c66a6EX21:c0b78a1c66a6Subsidiarie97%
    EX21:c51fc6fffbe3EX21:c51fc6fffbe3Subsidiarie97%
    EX21:ca8aaf67c3ccEX21:ca8aaf67c3ccSubsidiarie97%
    EX21:cd8450ded9a4EX21:cd8450ded9a4Subsidiarie97%
    EX21:ceb25a94ccefEX21:ceb25a94ccefSubsidiarie97%
    EX21:d0540ef98368EX21:d0540ef98368Subsidiarie97%
    EX21:d8a52699b59dEX21:d8a52699b59dSubsidiarie97%
    EX21:d921b1c9c21dEX21:d921b1c9c21dSubsidiarie97%
    EX21:dac27223f908EX21:dac27223f908Subsidiarie97%
    EX21:dd6972d5191aEX21:dd6972d5191aSubsidiarie97%
    EX21:dd7a1c7e63ccEX21:dd7a1c7e63ccSubsidiarie97%
    EX21:e425cf97a043EX21:e425cf97a043Subsidiarie97%
    EX21:e4955f2921ecEX21:e4955f2921ecSubsidiarie97%
    EX21:e5cd244633b0EX21:e5cd244633b0Subsidiarie97%
    EX21:e7745c2e084bEX21:e7745c2e084bSubsidiarie97%
    EX21:ea6ae1181e87EX21:ea6ae1181e87Subsidiarie97%
    EX21:eaca5d50316eEX21:eaca5d50316eSubsidiarie97%
    EX21:ec564512fdb6EX21:ec564512fdb6Subsidiarie97%
    EX21:ec5dceb7df85EX21:ec5dceb7df85Subsidiarie97%
    EX21:ecbf5fce915cEX21:ecbf5fce915cSubsidiarie97%
    EX21:f2eb9719f586EX21:f2eb9719f586Subsidiarie97%
    EX21:f3206b314b3aEX21:f3206b314b3aSubsidiarie97%
    EX21:f518c575b7efEX21:f518c575b7efSubsidiarie97%
    EX21:f71f45238ae6EX21:f71f45238ae6Subsidiarie97%
    EX21:f867d956844eEX21:f867d956844eSubsidiarie97%
    EX21:f8c11d3137a2EX21:f8c11d3137a2Subsidiarie97%
    EX21:fa9b3096a971EX21:fa9b3096a971Subsidiarie97%
    EX21:fc70b59bdca7EX21:fc70b59bdca7Subsidiarie97%
    EX21:fca5b2fd1c39EX21:fca5b2fd1c39Subsidiarie97%
    EX21:fe8e186e4fd3EX21:fe8e186e4fd3Subsidiarie97%
    EX21:ff8a683397a1EX21:ff8a683397a1Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison7 peers · vs MDLN · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    -176,3 vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    -181,3 vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    -164,7 vs self
    Div yield
    vs self
    ROE
    13,5 %
    vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    -177,0 vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    -122,1 vs self
    Div yield
    vs self
    ROE
    3,0 %
    vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    -194,1 vs self
    Div yield
    vs self
    ROE
    30,8 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,47
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    28
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-01 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$46,00
    Mean$53,56
    Median$55,00
    High$60,00
    Spot$51,00
    +5.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-128,0 %Bottom quartile
    Net Margin-168,3 %Bottom quartile
    ROE-9,7 %Below median
    Capex / Rev-5,7 %Bottom quartile
    D/E1,94Bottom quartile
    Cash Conv0,05Bottom quartile

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 29 605 565 sh1 exercises3 insiders
    • Golwas Douglas PChief Commercial Officer, 10% owner · Common Units of Medline Holdings, LP → Class A Common StockDisposed 100 000exercise · 2026-06-16
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Common Units → Class A Common StockDisposed 18 156 867conversion · 2026-05-21
    • BX Mozart ML-1 Holdco L.P.10% owner · Common Units of Medline Holdings, LP → Class A Common StockDisposed 1 489 924conversion · 2026-05-21
    • BX Mozart ML-1 Holdco L.P.10% owner · Common Units of Medline Holdings, LP → Class A Common StockDisposed 9 858 774conversion · 2026-05-21

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Modernland Realty Tbk PT Market data — financials · 2026-05-28
    • Modernland Realty Tbk PT Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    Net selling1 buys · 17 sellsnet -$6,7B19 insiders · last 365d
    • Golwas Douglas PChief Commercial Officer, 10% owner · Class A Common StockSold 61 966 @ $36,60$2,3M · 2026-06-16
    • Golwas Douglas PChief Commercial Officer, 10% owner · Class B Common StockOther 100 000 · 2026-06-16
    • Golwas Douglas PChief Commercial Officer, 10% owner · Class A Common StockOther 100 000 · 2026-06-16
    • Golwas Douglas PChief Commercial Officer, 10% owner · Class A Common StockSold 38 034 @ $37,05$1,4M · 2026-06-16
    • Abrams William JSee Remarks · Class A Common StockOther 1 308 @ $36,61$48K · 2026-06-15
    • Shryock Christopher PChief Human Resources Officer · Class A Common StockOther 872 @ $36,61$32K · 2026-06-15
    • Miller Stephen LChief Operating Officer · Class A Common StockOther 1 889 @ $36,61$69K · 2026-06-15
    • Liberman Alexander M.Chief Legal Officer · Class A Common StockOther 872 @ $36,61$32K · 2026-06-15
    • Laabs Amanda H.Chief Product Officer · Class A Common StockOther 1 889 @ $36,61$69K · 2026-06-15
    • Drazin Michael BChief Financial Officer · Class A Common StockOther 1 889 @ $36,61$69K · 2026-06-15
    • Golwas Douglas PChief Commercial Officer, 10% owner · Class A Common StockOther 1 889 @ $36,61$69K · 2026-06-15
    • Boyle James MDirector, Chief Executive Officer · Class A Common StockOther 2 370 @ $36,61$87K · 2026-06-15
    • Sweet Thomas WDirector · Class A Common StockOther 5 387 · 2026-06-11
    • GALANTI RICHARD ADirector · Class A Common StockOther 5 387 · 2026-06-11
    • Bluedorn Todd MDirector · Class A Common StockOther 5 387 · 2026-06-11
    • CORCORAN JESSI LPrincipal Accounting Officer · Class A Common StockBought 5 000 @ $34,15$171K · 2026-06-05
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockSold 753 528 @ $36,54$27,5M · 2026-05-28
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockSold 11 904 646 @ $36,54$435,0M · 2026-05-28
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockSold 1 262 726 @ $36,54$46,1M · 2026-05-28
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockOther 209 530 · 2026-05-28
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockOther 1 536 907 · 2026-05-28
    • Hellman & Friedman Capital Partners X (Parallel), L.P.10% owner · Class A Common StockOther 141 364 · 2026-05-28
    • HEALY PATRICK JDirector · Class A Common StockOther 179 762 · 2026-05-28
    • HEALY PATRICK JDirector · Class A Common StockOther 22 344 · 2026-05-28
    • BX Mozart ML-2 Holdco L.P.10% owner · Class A Common StockSold 19 712 326 @ $36,54$720,2M · 2026-05-28

    Short positioning

    29.5Mshares short-18.9% vs prior
    4.48days to cover
    41.2%short of daily vol
    26fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MDLN.JKCanonical
    IDX (Jakarta) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    MDLNEX21:016EX21:024EX21:080EX21:08fEX21:098EX21:0a1EX21:0a5EX21:0abEX21:0b4EX21:0dbDiversified Me
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 12.9%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -1.3%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -24.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 874.4%Derived (calculated)
    • Net margin (FY 2025-12-31): 4,069.4%Derived (calculated)
    • Gross margin (FY 2025-12-31): 26.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 19.4%Derived (calculated)
    • Return on assets (FY 2025-12-31): 3,006.4%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.29xDerived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
    • Return on equity (FY 2025-12-31): 10,775.8%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.79xDerived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 26.3%Derived (calculated)
    • Total assets (annual): USD 38.48BSEC XBRL filing
    • Current assets (annual): USD 10.68BSEC XBRL filing
    • Capex (annual): USD 447MSEC XBRL filing
    • R&D expense (annual): USD 80MSEC XBRL filing
    • Operating income (annual): USD 2.21BSEC XBRL filing
    • Revenue (annual): USD 28.43BSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-24 03:12 UTCHOLDERInstitutional holding changed
    2026-06-24 03:12 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-16 00:00 UTCINSIDER17 insider transactions — 2026-06 · net sell $4.0M 1 derivative
    2026-06-16INSIDERGolwas Douglas P sold 62.0k sh Class A Common Stock — Chief Commercial Officer, 10% owner ~$2.27M
    2026-06-16INSIDERGolwas Douglas P transacted 100.0k sh Class B Common Stock — Chief Commercial Officer, 10% owner
    2026-06-16INSIDERGolwas Douglas P sold 38.0k sh Class A Common Stock — Chief Commercial Officer, 10% owner ~$1.41M
    2026-06-16INSIDERGolwas Douglas P disposed of 100.0k sh Common Units of Medline Holdings, LP — Chief Commercial Officer, 10% owner
    2026-06-15INSIDERAbrams William J transacted 1.3k sh Class A Common Stock — See Remarks ~$48k
    2026-06-15INSIDERShryock Christopher P transacted 872 sh Class A Common Stock — Chief Human Resources Officer ~$32k
    2026-06-15INSIDERMiller Stephen L transacted 1.9k sh Class A Common Stock — Chief Operating Officer ~$69k
    2026-06-15INSIDERLiberman Alexander M. transacted 872 sh Class A Common Stock — Chief Legal Officer ~$32k
    2026-06-15INSIDERLaabs Amanda H. transacted 1.9k sh Class A Common Stock — Chief Product Officer ~$69k
    2026-06-15INSIDERDrazin Michael B transacted 1.9k sh Class A Common Stock — Chief Financial Officer ~$69k
    2026-06-15INSIDERGolwas Douglas P transacted 1.9k sh Class A Common Stock — Chief Commercial Officer, 10% owner ~$69k
    2026-06-15INSIDERBoyle James M transacted 2.4k sh Class A Common Stock — Director, Chief Executive Officer ~$87k
    2026-06-12FILING8-K filing →
    2026-06-11INSIDERSweet Thomas W transacted 5.4k sh Class A Common Stock — Director
    2026-06-11INSIDERGALANTI RICHARD A transacted 5.4k sh Class A Common Stock — Director
    2026-06-11INSIDERBluedorn Todd M transacted 5.4k sh Class A Common Stock — Director
    2026-06-05INSIDERCORCORAN JESSI L bought 5.0k sh Class A Common Stock — Principal Accounting Officer ~$171k
    2026-06-02FILING8-K filing →
    2026-05-28 00:00 UTCINSIDER23 insider transactions — 2026-05 · net sell $2.38B 3 derivative
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. sold 753.5k sh Class A Common Stock — 10% owner ~$27.53M
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. sold 11.90M sh Class A Common Stock — 10% owner ~$434.97M
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. sold 1.26M sh Class A Common Stock — 10% owner ~$46.14M
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. transacted 209.5k sh Class A Common Stock — 10% owner
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. transacted 1.54M sh Class A Common Stock — 10% owner
    2026-05-28INSIDERHellman & Friedman Capital Partners X (Parallel), L.P. transacted 141.4k sh Class A Common Stock — 10% owner
    2026-05-28INSIDERHEALY PATRICK J transacted 179.8k sh Class A Common Stock — Director
    2026-05-28INSIDERHEALY PATRICK J transacted 22.3k sh Class A Common Stock — Director
    2026-05-28INSIDERBX Mozart ML-2 Holdco L.P. sold 19.71M sh Class A Common Stock — 10% owner ~$720.24M
    2026-05-26FILING424B4 filing →
    2026-05-21INSIDERBX Mozart ML-1 Holdco L.P. disposed of 1.49M sh Common Units of Medline Holdings, LP — 10% owner
    Showing the 40 most recent of 57 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage